Patente
TICEBA verfügt als weltweit einziges Unternehmen über die Exklusivlizenz des Patents des Brigham and Women's Hospital, Lehrkrankenhaus der Harvard Medical School in Boston/USA, die dazu berechtigt die wertvollen ABCB5+ Stammzellen zu bestimmen und zu isolieren.
TICEBA ist exklusiver Lizenznehmer folgender Patente:
USA
- Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. "Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof." US Patent 6,846,883. January 25, 2005.
- Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. "Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-2 and uses thereof." US Patent 7,465,554. December 16, 2008.
- Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. "Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof." US Patent 8,076,091. December 13, 2011.
- Frank MH; The Brigham and Women’s Hospital, Inc. "ABCB5 positive mesenchymal stem cells as immunmodulators." US Patent 8,455,245. June 4, 2013.
Europe
- Frank MH and Sayegh MH; The Brigham and Women’s Hospital, Inc. "A gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof." European Patent EP1290028. 01. December 2010.